| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
We previously showed that WT1 immunotherapy is effective for recurrent malignant gliomas on the phase II clinical trial (J Neurosurg, 108(5):963-71, 2008).In this study we examined safety and efficacy of combination therapy with WT1 immunotherapy and Temozolomide (TMZ) for newly diagnosed malignant gliomas on phase I clinical trial and combination therapy of WT1-CTL peptide and WT1-helper peptide for recurrent gliomas . Both treatments were well tolerated and showed promising clinical outcomes.
|
